Characterization of the role of gamma2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome.
about
AMP-activated protein kinase, stress responses and cardiovascular diseasesMechanisms of sudden cardiac death: oxidants and metabolismActivation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heartAberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage.Defective Tbx2-dependent patterning of the atrioventricular canal myocardium causes accessory pathway formation in miceA novel PRKAG2 mutation in a Chinese family with cardiac hypertrophy and ventricular pre-excitationSGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathyRegulation of the muscle-specific AMP-activated protein kinase alpha2beta2gamma3 complexes by AMP and implications of the mutations in the gamma3-subunit for the AMP dependence of the enzyme.Identification of a novel de novo mutation associated with PRKAG2 cardiac syndrome and early onset of heart failureTransgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway.Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.Regulation of NAD(P)H oxidases by AMPK in cardiovascular systemsAMPK alterations in cardiac physiology and pathology: enemy or ally?Role of AMP-activated protein kinase in healthy and diseased hearts.Alterations in energy metabolism in cardiomyopathies.AMP activated protein kinase: a next generation target for total metabolic control.Mutation of Fnip1 is associated with B-cell deficiency, cardiomyopathy, and elevated AMPK activity.AMPK: Lessons from transgenic and knockout animalsAMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease.Cardiac metabolism and arrhythmias.Targeting AMPK for cardiac protection: opportunities and challenges.AMP-activated protein kinase regulation and biological actions in the heart.AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease.Misinterpretation of the mouse ECG: 'musing the waves of Mus musculus'.Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?Physiological Expression of AMPKγ2RG Mutation Causes Wolff-Parkinson-White Syndrome and Induces Kidney Injury in Mice.Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome.Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade.Cardiac glycogen accumulation after dexamethasone is regulated by AMPK.Mammalian γ2 AMPK regulates intrinsic heart rate.Maternal diabetes adversely affects AMP-activated protein kinase activity and cellular metabolism in murine oocytes.
P2860
Q24610297-459CD4A9-B77B-4A20-92E7-3DC5FA21AF70Q27024176-E3731026-6FA3-4BA6-B9F1-7AE8849B5C80Q28574917-58E2BB8E-C8B7-4136-B9D0-A38875CE5251Q30445033-707FA7E5-5F5E-4A7C-9C48-CF70760F124AQ30497991-ED4643AD-F715-4C88-90C2-9FF06251AA5DQ33729245-0DED99CE-FBB6-4A30-9C86-93DBA7664540Q34101200-7D65CE7E-3FEA-4C1D-A7C0-D1095024B01EQ34630778-5AE96121-620B-4FE6-B032-295FC0A6E715Q34760564-0D55C85F-B550-41AB-B665-68F93228D45AQ35026241-758228D2-18F9-4F68-9FB6-0612B37874FDQ35768634-E4022D42-C83E-433C-8489-48E0AFE47B38Q35810625-C02585ED-977B-4C72-BE29-A6A9FE2CB7EFQ35925959-EC99D677-7B3F-45A7-AD9F-27C38515DFF5Q36475855-BBB100DE-827F-4725-8277-999FE1A36DADQ36537821-655CCFFB-78B3-4E7B-B433-EF1F5F8360F9Q36970329-B5E74F30-E73D-4D2B-BB62-30D8F2FBCE62Q37030884-8290C5D0-A30F-4879-BB81-8B99AC3524B2Q37065314-0582A8DB-9B82-4257-BB33-2369F9B26597Q37153612-8D28955B-BAA4-4720-81DD-3C39FF0CDB57Q37411713-4BE67064-12A9-4F2D-8DBD-FEAAF1058188Q37609734-C0F48C82-6864-4FF9-931E-D4044F875D29Q37819301-83DA7A39-EF6B-479C-9AA3-8D5C951F0CB9Q38039283-5F927077-06C6-4446-8A9C-40132D2C62C0Q38211516-91FB979E-6AFF-4C7C-8BDA-B7B9296D927DQ38254729-16CC3F66-3485-4C37-8E9D-222251DC6CFFQ38999231-1998D0F7-204A-4F72-B833-3B0A79366A78Q39398110-74F8B359-E11F-4C67-98FB-A71544982D3FQ40602766-704006B4-62C6-4D86-B804-A384AFC0B48EQ42160057-38E42287-188E-47C9-A8E4-1091BDE9ABE8Q46403678-73C4A80F-D533-4379-A82D-B21BA2A8EFBCQ46744561-4AE9C202-AA4E-47E5-860C-BC909D751983Q48786022-19F274C5-57C9-493D-92E9-77D451239804
P2860
Characterization of the role of gamma2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Characterization of the role o ...... olff-Parkinson-White syndrome.
@ast
Characterization of the role o ...... olff-Parkinson-White syndrome.
@en
type
label
Characterization of the role o ...... olff-Parkinson-White syndrome.
@ast
Characterization of the role o ...... olff-Parkinson-White syndrome.
@en
prefLabel
Characterization of the role o ...... olff-Parkinson-White syndrome.
@ast
Characterization of the role o ...... olff-Parkinson-White syndrome.
@en
P2093
P2860
P50
P1476
Characterization of the role o ...... olff-Parkinson-White syndrome.
@en
P2093
Gaëtane Noël
Helen R Whitrow
Joanna K Davies
Jürgen E Schneider
Robert Grignani
Tyrone D Daniel
P2860
P304
P356
10.1152/AJPHEART.01020.2005
P577
2005-12-09T00:00:00Z